Eli Lilly Just Beat Its Own Best-Selling Drug. On Purpose.
Eli Lilly's experimental obesity combo EloraTZP crushed its own blockbuster Zepbound in a head-to-head trial, with patients losing 23.3% of body weight versus 14.8%. It's a bold move that redefines the obesity drug arms race with Novo Nordisk.
Most companies spend years trying to beat the competition. Eli Lilly decided to beat itself.
The pharma giant just reported that its experimental obesity combo, EloraTZP, outperformed its own blockbuster Zepbound in a head-to-head trial. Not by a little. Patients on the highest dose of the new drug lost 23.3% of their body weight over 48 weeks, compared to 14.8% for those on the highest dose of Zepbound.
That's like running a 4:00 mile, then coming back a year later and running a 3:05. Against yourself.
Why Would You Cannibalize Your Own Bestseller?
It sounds counterintuitive. Zepbound (the brand name for tirzepatide in obesity) is one of the most commercially dominant drugs on the planet right now. In 2025, it pulled in roughly $13.5 billion in sales, growing 175% year over year. By Q4 of last year, it was generating over $4.2 billion per quarter in the U.S. alone. One industry analysis pegged Zepbound at 71% of new U.S. obesity prescriptions in Q3 2025.
So why build a drug designed to make your cash cow look worse by comparison?
Because in the obesity drug wars, standing still means falling behind. Novo Nordisk is pushing hard with its own next-generation candidates, and the market rewards whoever delivers the most weight loss with tolerable side effects. Lilly isn't cannibalizing Zepbound; it's building the sequel before anyone else can write a better script.
What EloraTZP Actually Is (and Why It Works Better)
Zepbound works by mimicking two gut hormones: GLP-1 and GIP. Think of them as your body's natural appetite brakes. When you eat, these hormones tell your brain you're full and slow down your digestion. Zepbound hits both of those signals at once, which is why it was such a leap forward over older drugs that only targeted one.
EloraTZP takes that same foundation and adds a third ingredient: eloralintide, a drug that mimics another hormone called . Amylin is released by the same pancreatic cells that produce insulin. It slows stomach emptying, reduces appetite, and helps regulate blood sugar.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
amylin
If Zepbound is a double shot of espresso, EloraTZP is a triple. Same base ingredients, but with an extra kick that apparently makes a meaningful difference.
The combination drug is literally tirzepatide (the active ingredient in Zepbound) co-formulated with eloralintide. That's what the name "EloraTZP" reflects. It's not a totally new molecule; it's an upgraded version of what already works.
The Numbers Tell a Clear Story
The phase 2 trial enrolled patients with obesity or overweight and type 2 diabetes, which is an important detail. People with diabetes typically lose less weight on GLP-1 drugs than people without it, so these results may actually understate what EloraTZP could do in a broader population.
At the highest tested doses over 48 weeks, EloraTZP delivered 23.3% body weight loss versus 14.8% for Zepbound. The phase 2 presentation also showed about 23% weight loss for the combo, compared to 15% for Zepbound and 11.1% for eloralintide on its own.
That last comparison matters. Eloralintide alone isn't anything special. Tirzepatide alone is great. But combining them creates something meaningfully better than either piece, which is exactly the kind of synergy (pardon the corporate word) that drug developers dream about.
A Few Asterisks Worth Reading
Before anyone declares Zepbound obsolete, a few caveats.
First, this is phase 2 data. Phase 2 trials are mid-stage studies designed to find the right dose and get early signals of effectiveness. They're promising, but they're not the final word. Phase 3 trials (the large, definitive studies needed for FDA approval) haven't started yet, though Lilly has said it plans to kick off late-stage trials in Q4 2026.
Second, we don't have much public detail on side effects, dropout rates, or tolerability. Weight loss numbers are flashy, but the real-world success of an obesity drug depends heavily on whether patients can stay on it without feeling miserable. GLP-1 drugs are already known for nausea and GI issues; adding an amylin agonist could potentially make that worse. We'll need phase 3 data to know for sure.
Third, the Zepbound doses used in this trial may not represent every possible real-world dosing scenario. Cross-comparisons, even in head-to-head studies, always come with fine print.
Novo Nordisk Isn't Just Watching
The obesity drug market is shaping up like a heavyweight title fight, and Novo Nordisk has no intention of surrendering the belt.
Novo's nearest counterpunch is CagriSema, a combination of cagrilintide (another amylin-targeting drug, interestingly) and semaglutide (the active ingredient in Wegovy and Ozempic). CagriSema is much further along than EloraTZP: Novo has already filed for U.S. approval, with a regulatory decision expected in Q4 2026. And Novo has claimed that CagriSema showed greater weight loss than a Lilly rival in a late-stage study, though cross-trial comparisons are notoriously tricky.
Behind CagriSema, Novo has amycretin (now renamed zenagamtide), a next-generation molecule entering phase 3 in 2026 with both injectable and oral versions in development. The oral option could be a major differentiator if it delivers similar efficacy to injections; many patients strongly prefer a pill over a weekly shot.
The competitive picture is becoming clear: both companies are pursuing the same basic strategy of combining amylin signaling with incretin hormones (GLP-1 and/or GIP). The race is about who can execute fastest, generate the cleanest data, and get to market first with a next-gen product.
Lilly's Ridiculous Depth Chart
What makes Lilly's position so formidable isn't just EloraTZP. It's the sheer depth of their obesity pipeline. Consider what else they have cooking:
Retatrutide is a triple agonist that hits GLP-1, GIP, and glucagon receptors. It's in late-stage trials, with Lilly planning to seek approval in early 2027. If the amylin combo is like adding a third espresso shot, retatrutide is like adding a completely different ingredient to the coffee.
Orforglipron is an oral GLP-1 drug, which would give Lilly a pill option for patients who don't want injections. Then there's bimagrumab (targeting muscle preservation during weight loss), naperiglipron (another oral candidate), and even a phase 1 asset called LY4329090 extending the pipeline further out.
Lilly isn't betting on one horse. They've got an entire stable, each approaching obesity from a slightly different angle. If any single program stumbles, they have backups.
What Wall Street Is Thinking
Analysts have coalesced around a pretty simple thesis: Lilly's pipeline depth is the bullish case, and this data only strengthens it. The EloraTZP results show that Lilly can layer improvements on top of its own best-in-class drug, which raises the competitive bar for everyone else.
The broader market tone treats efficacy as the key battleground now. Investors are using head-to-head superiority as the benchmark for picking obesity drug winners, and Lilly just demonstrated it can beat itself. That's a powerful signal.
Still, there's appropriate caution. Moving from encouraging mid-stage data to a registrational program and eventually commercialization takes years and billions of dollars. Phase 2 results don't always hold up in phase 3. And the obesity market is growing so fast that there may be room for multiple winners, at least for now.
The Bigger Picture
The obesity drug market has gone from "niche" to "one of the biggest pharmaceutical categories in history" in about three years. Lilly's combined tirzepatide franchise (Mounjaro for diabetes plus Zepbound for obesity) hit $36.5 billion in 2025 sales, surpassing even Merck's legendary Keytruda at the franchise level.
But this is still the early innings. Current GLP-1 drugs produce 15-20% weight loss on average. EloraTZP is pushing past 23%. The question for the next few years is whether someone can crack 30% or more while keeping side effects manageable.
Lilly just showed that the ceiling keeps going up. And for a company that already owns the biggest drug in the space, that's exactly where they want the conversation to be. Why fight over today's market when you can define tomorrow's?
The late-stage trials starting later this year will tell us whether EloraTZP's early promise translates into something real. Until then, Lilly's strategy is clear: keep raising the bar, even if the bar you're clearing is your own.
Science & Discovery4 min read
The Nobel Prize That Explains Why Your Medication Only Works One Way
The 2026 Nobel Prize in Chemistry went to two scientists who figured out how to stop molecules from being made backwards. More than half of all drugs on the market depend on this kind of chemistry, and the implications for pharma are bigger than you think.
